Connective tissue disease-associated pulmonary arterial hypertension

Rheumatic Disease Clinics of North America

Volumn 41, Issue 2, 2015, Pages 295-313

  Sung, Yon K ^a   Chung, Lorinda ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Connective tissue disease; Mixed connective tissue disease; Pulmonary arterial hypertension; Pulmonary hypertension; Systemic lupus erythematosus; Systemic sclerosis

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CYCLOPHOSPHAMIDE; DIGOXIN; DIURETIC AGENT; ENDOTHELIAL CELL ANTIBODY; ENDOTHELIN RECEPTOR ANTAGONIST; GLUCOCORTICOID; LEUKOTRIENE B4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE; RIBONUCLEOPROTEIN ANTIBODY;

ANTICOAGULANT THERAPY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG MECHANISM; DRUG MEGADOSE; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; HEART CATHETERIZATION; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE PRESSURE; HUMAN; HYPERVOLEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; META ANALYSIS (TOPIC); MIXED CONNECTIVE TISSUE DISEASE; MONOTHERAPY; NEW YORK HEART ASSOCIATION CLASS; OXYGEN THERAPY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); POLYMYOSITIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SCREENING; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; TREATMENT DURATION; VACCINATION; COMPLICATION; HYPERTENSION, PULMONARY; MASS SCREENING;

CONNECTIVE TISSUE DISEASES; HUMANS; HYPERTENSION, PULMONARY; MASS SCREENING;

EID: 84926216040     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2015.01.003     Document Type: Review

References (84)

1. Hoeper M.M., Bogaard H.J., Condliffe R., et al. Definitions and diagnosis of pulmonary hypertension. JAm Coll Cardiol 2013, 62:D42-D50.
2. Simonneau G., Gatzoulis M.A., Adatia I., et al. Updated clinical classification of pulmonary hypertension. JAm Coll Cardiol 2013, 62:D34-D41.
3. Stacher E., Graham B.B., Hunt J.M., et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012, 186:261-272.
4. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
5. Chung L., Liu J., Parsons L., et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010, 138:1383-1394.
6. Condliffe R., Kiely D.G., Peacock A.J., et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009, 179:151-157.
7. Galie N., Corris P.A., Frost A., et al. Updated treatment algorithm of pulmonary arterial hypertension. JAm Coll Cardiol 2013, 62:D60-D72.
8. Ngian G.S., Stevens W., Prior D., et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2012, 14:R213.
9. Hao Y.J., Jiang X., Zhou W., et al. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. Eur Respir J 2014, 44:963-972.
10. Jeon C.H., Chai J.Y., Seo Y.I., et al. Pulmonary hypertension associated with rheumatic diseases: baseline characteristics from the Korean registry. Int J Rheum Dis 2012, 15:e80-e89.
11. Finkelhor R.S., Lewis S.A., Pillai D. Limitations and strengths of Doppler/echo pulmonary artery systolic pressure-right heart catheterization correlations: a systematic literature review. Echocardiography 2014, 32:10-18.
12. McLaughlin V.V., Archer S.L., Badesch D.B., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009, 119:2250-2294.
13. Mukerjee D., St George D., Coleiro B., et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003, 62:1088-1093.
14. Hachulla E., Gressin V., Guillevin L., et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005, 52:3792-3800.
15. Phung S., Strange G., Chung L.P., et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 2009, 39:682-691.
16. Coghlan J.G., Denton C.P., Grunig E., et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014, 73:1340-1349.
17. Hachulla E., de Groote P., Gressin V., et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009, 60:1831-1839.
18. Li M., Zhang W., Leng X., et al. Chinese SLE Treatment and Research group (CSTAR) registry: I. major clinical characteristics of Chinese patients with systemic lupus erythematosus. Lupus 2013, 22:1192-1199.
19. Ruiz-Irastorza G., Garmendia M., Villar I., et al. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmun Rev 2013, 12:410-415.
20. Gunnarsson R., Andreassen A.K., Molberg O., et al. Prevalence of pulmonary hypertension in an unselected, mixed connective tissue disease cohort: results of a nationwide, Norwegian cross-sectional multicentre study and review of current literature. Rheumatology 2013, 52:1208-1213.
21. Dawson J.K., Goodson N.G., Graham D.R., et al. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology 2000, 39:1320-1325.
22. Keser G., Capar I., Aksu K., et al. Pulmonary hypertension in rheumatoid arthritis. Scand J Rheumatol 2004, 33:244-245.
23. Udayakumar N., Venkatesan S., Rajendiran C. Pulmonary hypertension in rheumatoid arthritis-relation with the duration of the disease. Int J Cardiol 2008, 127:410-412.
24. Mustafa K.N., Dahbour S.S. Clinical characteristics and outcomes of patients with idiopathic inflammatory myopathies from Jordan 1996-2009. Clin Rheumatol 2010, 29:1381-1385.
25. Vassiliou V.A., Moyssakis I., Boki K.A., et al. Is the heart affected in primary Sjogren's syndrome? An echocardiographic study. Clin Exp Rheumatol 2008, 26:109-112.
26. Kobak S., Kalkan S., Kirilmaz B., et al. Pulmonary arterial hypertension in patients with primary Sjogren's syndrome. Autoimmune Dis 2014, 2014:710401.
27. Taraseviciene-Stewart L., Nicolls M.R., Kraskauskas D., et al. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med 2007, 175:1280-1289.
28. Tamosiuniene R., Tian W., Dhillon G., et al. Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res 2011, 109:867-879.
29. Cines D.B., Lyss A.P., Reeber M., et al. Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus. JClin Invest 1984, 73:611-625.
30. Dieude M., Senecal J.L., Raymond Y. Induction of endothelial cell apoptosis by heat-shock protein 60-reactive antibodies from anti-endothelial cell autoantibody-positive systemic lupus erythematosus patients. Arthritis Rheum 2004, 50:3221-3231.
31. Worda M., Sgonc R., Dietrich H., et al. Invivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum 2003, 48:2605-2614.
32. Bordron A., Dueymes M., Levy Y., et al. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. JClin Invest 1998, 101:2029-2035.
33. Kaneko K., Savage C.O., Pottinger B.E., et al. Antiendothelial cell antibodies can be cytotoxic to endothelial cells without cytokine pre-stimulation and correlate with ELISA antibody measurement in Kawasaki disease. Clin Exp Immunol 1994, 98:264-269.
34. Sgonc R., Gruschwitz M.S., Boeck G., et al. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000, 43:2550-2562.
35. Negi V.S., Tripathy N.K., Misra R., et al. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. JRheumatol 1998, 25:462-466.
36. Song J., Park Y.B., Lee W.K., et al. Clinical associations of anti-endothelial cell antibodies in patients with systemic lupus erythematosus. Rheumatol Int 2000, 20:1-7.
37. Chan T.M., Cheng I.K. Aprospective study on anti-endothelial cell antibodies in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1996, 78:41-46.
38. Navarro M., Cervera R., Font J., et al. Anti-endothelial cell antibodies in systemic autoimmune diseases: prevalence and clinical significance. Lupus 1997, 6:521-526.
39. Liu X.D., Guo S.Y., Yang L.L., et al. Anti-endothelial cell antibodies in connective tissue diseases associated with pulmonary arterial hypertension. JThorac Dis 2014, 6:497-502.
40. Tian W., Jiang X., Tamosiuniene R., et al. Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. Sci Transl Med 2013, 5:200ra117.
41. van Bon L., Affandi A.J., Broen J., et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. NEngl J Med 2014, 370:433-443.
42. Wang Y., Kahaleh B. Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma. JCell Mol Med 2013, 17:1291-1299.
43. Satoh M., Krzyszczak M.E., Li Y., et al. Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study. Arthritis Res Ther 2011, 13:R73.
44. Fredi M., Cavazzana I., Quinzanini M., et al. Rare autoantibodies to cellular antigens in systemic lupus erythematosus. Lupus 2014, [Epub ahead of print].
45. Okawa-Takatsuji M., Aotsuka S., Uwatoko S., et al. Increase of cytokine production by pulmonary artery endothelial cells induced by supernatants from monocytes stimulated with autoantibodies against U1-ribonucleoprotein. Clin Exp Rheumatol 1999, 17:705-712.
46. Steen V., Medsger T.A. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003, 48:516-522.
47. Stupi A.M., Steen V.D., Owens G.R., et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986, 29:515-524.
48. Allanore Y., Borderie D., Avouac J., et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008, 58:284-291.
49. Shah A.A., Chung S.E., Wigley F.M., et al. Changes in estimated right ventricular systolic pressure predict mortality and pulmonary hypertension in a cohort of scleroderma patients. Ann Rheum Dis 2013, 72:1136-1140.
50. Valerio C.J., Schreiber B.E., Handler C.E., et al. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. Arthritis Rheum 2013, 65:1074-1084.
51. Heresi G.A., Minai O.A., Tonelli A.R., et al. Clinical characterization and survival of patients with borderline elevation in pulmonary artery pressure. Pulm Circ 2013, 3:916-925.
52. Yaqub A., Chung L. Epidemiology and risk factors for pulmonary hypertension in systemic sclerosis. Curr Rheumatol Rep 2013, 15:302.
53. Gourh P., Arnett F.C., Assassi S., et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009, 11:R147.
54. Kollert F., Christoph S., Probst C., et al. Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis. Arthritis Care Res 2013, 65:281-287.
55. Fois E., Le Guern V., Dupuy A., et al. Noninvasive assessment of systolic pulmonary artery pressure in systemic lupus erythematosus: retrospective analysis of 93 patients. Clin Exp Rheumatol 2010, 28:836-841.
56. Prabu A., Patel K., Yee C.S., et al. Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. Rheumatology 2009, 48:1506-1511.
57. Thakkar V., Stevens W.M., Moore O.A., et al. Performance of screening algorithms in systemic sclerosis-related pulmonary arterial hypertension: a systematic review. Intern Med J 2013, 43:751-760.
58. Saukkonen K., Tan T.C., Sharma A., et al. Case records of the Massachusetts General Hospital. Case 9-2014. A 34-year-old woman with increasing dyspnea. NEngl J Med 2014, 370:1149-1157.
59. Prete M., Fatone M.C., Vacca A., et al. Severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature. Clin Exp Rheumatol 2014, 32:267-274.
60. Kuwana M., Watanabe H., Matsuoka N., et al. Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trials. BMJ Open 2013, 3(8):e003113.
61. Taichman D.B., Ornelas J., Chung L., et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest 2014, 146:449-475.
62. Olsson K.M., Delcroix M., Ghofrani H.A., et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014, 129:57-65.
63. Nikpour M., Stevens W., Proudman S.M., et al. Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated?. Intern Med J 2013, 43:599-603.
64. Sanchez O., Sitbon O., Jais X., et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006, 130:182-189.
65. Miyamichi-Yamamoto S., Fukumoto Y., Sugimura K., et al. Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. Circ J 2011, 75:2668-2674.
66. Jais X., Launay D., Yaici A., et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008, 58:521-531.
67. Tanaka E., Harigai M., Tanaka M., et al. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. JRheumatol 2002, 29:282-287.
68. Kato M., Kataoka H., Odani T., et al. The short-term role of corticosteroid therapy for pulmonary arterial hypertension associated with connective tissue diseases: report of five cases and a literature review. Lupus 2011, 20:1047-1056.
69. Suzuki C., Takahashi M., Morimoto H., et al. Mycophenolate mofetil attenuates pulmonary arterial hypertension in rats. Biochem Biophys Res Commun 2006, 349:781-788.
70. Zheng Y., Li M., Zhang Y., et al. The effects and mechanisms of mycophenolate mofetil on pulmonary arterial hypertension in rats. Rheumatol Int 2010, 30:341-348.
71. Morelli S., Giordano M., De Marzio P., et al. Pulmonary arterial hypertension responsive to immunosuppressive therapy in systemic lupus erythematosus. Lupus 1993, 2:367-369.
72. McGonagle D., Tan A.L., Madden J., et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology 2008, 47:552-553.
73. Braun-Moscovici Y., Butbul-Aviel Y., Guralnik L., et al. Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience. Rheumatol Int 2013, 33:1495-1504.
74. Hennigan S., Channick R.N., Silverman G.J. Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report. Lupus 2008, 17:754-756.
75. Jordan S., Distler J.H., Maurer B., et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2014, [Epub ahead of print].
76. Daoussis D., Liossis S.N., Tsamandas A.C., et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 2010, 49:271-280.
77. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66:940-944.
78. Tyndall A.J., Bannert B., Vonk M., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010, 69:1809-1815.
79. Chung L., Farber H.W., Benza R., et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the reveal registry. Chest 2014, 146:1494-1504.
80. Launay D., Sitbon O., Hachulla E., et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis 2013, 72:1940-1946.
81. Lefevre G., Dauchet L., Hachulla E., et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum 2013, 65:2412-2423.
82. Chung L., Domsic R.T., Lingala B., et al. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res 2014, 66:489-495.
83. Chung S.M., Lee C.K., Lee E.Y., et al. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol 2006, 25:866-872.
84. Launay D., Hachulla E., Hatron P.Y., et al. Pulmonary arterial hypertension: a rare complication of primary Sjogren syndrome: report of 9 new cases and review of the literature. Medicine 2007, 86:299-315.